PROM1 and adenocarcinoma: However, a similar study found no correlation between cytoplasmic CD133 and patient survival[52], while Kojima et al.[53] observed no differences in DFS between CD133-positive and-negative patients, although they considered CD133 overexpression to be a risk factor in patients with well- and moderately-differentiated adenocarcinomas.